Enlight-LN Registry: Baseline Demographics and Clinical Characteristics of an Initial Cohort of Patients Treated with Voclosporin for Lupus Nephritis in the United States (KIDNEY WEEK 2024) - Sep 23, 2024 - Abstract #TH-PO653; Pres time: Oct 24, 2024; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "A total of 107 patients were on concomitant immunosuppression at voclosporin initiation (most commonly, antimalarials, 72.4%; MMF/mycophenolate sodium, 70.7%; belimumab, 13%). Baseline data on this initial cohort of patients are reflective of the larger LN population in the US, including high percentages of Black and Hispanic and/or Latino patients. Enrollment of additional patients and ongoing data collection will provide valuable insight into the real-world utilization of voclosporin."
Clinical • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Niloofar Nobakht, MD, FASN; Laura B. Geraldino-Pardilla, MD, MS; Leanna Marderian Wise, MD, MPH; Mohammad Kamgar, MD, FASN; Lily Cipolla, PharmD; Lucy S. Hodge, PharmD, PhD; Keelin Dahl, PharmD
|